Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $35 to $40.
May 13, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo's updated Overweight rating and raised price target from $35 to $40 for Spyre Therapeutics indicates a positive outlook on the company's stock.
Analyst ratings and price target adjustments are significant indicators for stock performance. An increase in the price target, especially from a reputable financial institution like Wells Fargo, suggests a strong belief in the company's future growth and performance. This is likely to influence investor sentiment positively, leading to potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100